|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Studies in animal models have shown that systemic immunization with a papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral protein, can confer protection against subsequent experimental challenge with the homologous virus. Here we report results of a double-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Alum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins,
http://linkedlifedata.com/resource/pubmed/chemical/MF59 oil emulsion,
http://linkedlifedata.com/resource/pubmed/chemical/Papillomavirus Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Polysorbates,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Squalene,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/aluminum sulfate
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
pubmed-author:DillnerJJ,
pubmed-author:HarroC DCD,
pubmed-author:HildesheimAA,
pubmed-author:KarronR ARA,
pubmed-author:LowyD RDR,
pubmed-author:MastT CTC,
pubmed-author:MurphyB RBR,
pubmed-author:PangY YYY,
pubmed-author:ReynoldsM JMJ,
pubmed-author:RobinsonRR,
pubmed-author:RodenR BRB,
pubmed-author:SchillerJ TJT,
pubmed-author:WangZZ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
284-92
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11181775-Adjuvants, Immunologic,
pubmed-meshheading:11181775-Adult,
pubmed-meshheading:11181775-Alum Compounds,
pubmed-meshheading:11181775-Antibodies, Viral,
pubmed-meshheading:11181775-Baculoviridae,
pubmed-meshheading:11181775-Double-Blind Method,
pubmed-meshheading:11181775-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:11181775-Female,
pubmed-meshheading:11181775-Humans,
pubmed-meshheading:11181775-Immunization Schedule,
pubmed-meshheading:11181775-Immunoglobulins,
pubmed-meshheading:11181775-Injections, Intramuscular,
pubmed-meshheading:11181775-Male,
pubmed-meshheading:11181775-Papillomaviridae,
pubmed-meshheading:11181775-Papillomavirus Vaccines,
pubmed-meshheading:11181775-Polysorbates,
pubmed-meshheading:11181775-Recombinant Proteins,
pubmed-meshheading:11181775-Reference Values,
pubmed-meshheading:11181775-Squalene,
pubmed-meshheading:11181775-Viral Vaccines
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
|
|
pubmed:affiliation |
Center for Immunization Research, Department of International Medicine, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
